Aprea reports Phase 1 safety data for ATRN-119; no hematologic or liver toxicities; WEE1i ATRN-1051 IND planned Q4 2023

Aprea Therapeutics, Inc.

ATRN-119 Phase 1/2a dose escalation shows no hematologic or liver toxicities across first three cohorts (50, 100, 200 mg) in heavily pretreated solid tumor patients.
One stable disease observed at 50 mg low dose; dose expansion cohort on track for Q2 2024; currently enrolling 350 mg cohort.
Pre-clinical data for WEE1i ATRN-1051 shows high selectivity for WEE1 and low off-target activity against PLK kinases; IND submission planned for Q4 2023.
ATRN-1051 preclinical findings also show limited effects on red blood cell counts, hERG inhibition, and body weight loss compared to other WEE1 inhibitors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.